WAAG
CGTX icon

Wealth Alliance Advisory Group’s Cognition Therapeutics CGTX Stock Holding History

Wealth Alliance Advisory Group’s Portfolio CGTX Stock Details CGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-13,874
Closed -$29.1K – 168
2022
Q4 		$29.1K Sell
13,874
-4,626
-25% -$9.34K 0.01% 169
2022
Q3 		$35K Buy
+18,500
New +$38.5K 0.02% 154

Other funds holding CGTX

PFO
Pathstone Family Office Englewood, New Jersey $13.1B AUM 21.02% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
CC
Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return
PWM
Perigon Wealth Management San Francisco, California $5.51B AUM 24.51% 1-Year Est. Return
AFG
American Financial Group Cincinnati, Ohio $270M AUM 3.25% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
KAS
Kestra Advisory Services Austin, Texas $26.4B AUM 21.05% 1-Year Est. Return

Wealth Alliance Advisory Group's CGTX Position: Q1 2023 in Review

Wealth Alliance Advisory Group sold out of Cognition Therapeutics (CGTX) in Q1 2023, closing a stake of 13,874 shares — an estimated $29.1K sold.

Wealth Alliance Advisory Group first reported a position in CGTX in Q3 2022 and held it in 2 quarters. The position peaked at $35K in Q3 2022. 32 funds tracked by Wall St. Rank hold CGTX as of Q1 2023.

  • Wealth Alliance Advisory Group reported no remaining Cognition Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Wealth Alliance Advisory Group sold 13,874 Cognition Therapeutics shares in Q1 2023, an estimated $29.1K.
  • Wealth Alliance Advisory Group first reported a position in Cognition Therapeutics in Q3 2022 and held it in 2 quarters.
  • Wealth Alliance Advisory Group's Cognition Therapeutics position peaked at $35K in Q3 2022.
  • 32 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q1 2023.

Based on Wealth Alliance Advisory Group's 13F filing for Q1 2023, filed 2 May 2023.